• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Biotech Market
Biotech News
Biotech Stocks
  • Biotech Market
  • Biotech News
  • Biotech Stocks

Hoth Therapeutics Announces Pricing of Initial Public Offering and Trading on the Nasdaq

Written by Jocelyn Aspa
|
Feb. 15, 2019 08:37AM PST

Hoth Therapeutics (NASDAQ:HOTH) has announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share. As quoted in the press release:  All shares of common stock are being offered by Hoth. In addition, Hoth has granted the underwriters a 30-day option …

Hoth Therapeutics (NASDAQ:HOTH) has announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share.

As quoted in the press release:

 All shares of common stock are being offered by Hoth. In addition, Hoth has granted the underwriters a 30-day option to purchase up to an additional 187,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments, if any.

The Company’s common stock is expected to commence trading on The Nasdaq Capital Market, on February 15, 2019 under the ticker symbol “HOTH”.  The offering is expected to close on February 20, 2019, subject to the satisfaction of customary closing conditions.

Laidlaw & Company (UK) Ltd. is acting as the sole book-running manager for the offering. The Benchmark Company, LLC is serving as Qualified Independent Underwriter for the offering.

The offering is being made solely by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from Laidlaw & Company (UK) Ltd., Attention: Syndicate Department, 521 Fifth Avenue, New York, NY 10175, by telephone at (212) 953-4900 or by email at syndicate@laidlawltd.com.

Click here to read the full press release.

initial public offering
The Conversation (0)

Go Deeper

AI Powered
PharmaTher Holdings Ltd Com

PharmaTher Holdings Ltd Com

OHA Invests Euro41M in IDEAL Holdings

Latest News

Outlook Reports world

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
  • Energy
    • Uranium
    • Oil and Gas
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Industrial Metals
  • Agriculture
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Gaming
    • Cleantech
    • Emerging Tech
Life Science
    • Biotech
    • Cannabis
    • Psychedelics
    • Pharmaceuticals

Featured Biotech Investing Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES